Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non‐small‐cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2249|180|3|467-474

ISSN： 0009-9104

Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.180, Iss.3, 2015-06, pp. : 467-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sublobar Resection, Radiofrequency Ablation or Radiotherapy in Stage I Non-Small Cell Lung Cancer

By  

Respiration, Vol. 89, Iss. 6, 2015-04 ,pp. : 550-557

Karger

Access to resources Recommend Favorite

Radiofrequency ablation in high‐risk stage I non–small cell lung cancer

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3393-3394

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Pathology of Non-Small-Cell Lung Cancer

By  

Respiration, Vol. 72, Iss. 3, 2005-06 ,pp. : 313-330

Karger

Access to resources Recommend Favorite

Hycamtin in the Therapy of Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 18-21

Karger

Access to resources Recommend Favorite

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite